ClinicalTrials.gg
RecruitingNCT07756034ONCO-OLIVIAUpdated Aug 10, 2026

Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer

An observational study in Cancer, Solid Tumor Cancer and Pediatric Acute Myeloid Leukemia, sponsored by Tempus AI. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-08-10.

Primary conditionHematologic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hematologic Neoplasms
Why
  1. The study's listed conditions name Hematologic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tempus AI · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
30th of 157
1,000 · median 150
Started
2026
with 37 others
Observational
157 of 821
58 open now
Primary completion
2031-07
later than 247 of 273 live
Registered
817th of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 30th largest by planned enrollment of the 157 observational ones that give a count, is one of 38 that started in 2026, is one of 157 observational ones, reaches primary completion later than 247 of the 273 other live ones, and was the 817th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

175 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus.

Olivia will serve as the primary interface for eConsent and enrollment into the registry. The platform will also help create a retrospective and prospective registry by working with over 1,000 healthcare systems to combine electronic health records (EHR) and Patient Reported Outcomes (PROs) in a single spot.

There may be sub-studies as an add-on to this parent protocol. The sub-studies will address specific goals of the targeted research activities and will usually include additional information specific to each research study.

Read the detailed description

Olivia will capture data through continuous data accrual, multimodal integration, and longitudinal depth. Data may be collected from areas including, but not limited to, clinical/EHR, pathology/genomics, imaging, PROs, or linkage.

Primary pathway: Olivia-enabled remote eConsent/authorization under HIPAA Right of Access and TEFCA Individual Access Services (IAS) to retrieve medical records. Data are curated into de-identified/coded, auditable datasets for research and potential secondary research and/or regulatory uses. Retrospective capture reaches back to diagnosis or earlier when available. Participation does not affect clinical care or access to care, and no investigational treatments or research-mandated procedures are administered.

Sub-studies will routinely include supplemental information specific to each research project, including but not limited to the following: purpose, objective(s), background, design, population(s) of interest (e.g., inclusion or exclusion criteria), analytic method(s), storage and archival considerations, etc.

Depending on the nature of the research partnership, sub-studies may designate a co-Principal Investigator and/or co-Sponsor to support the sub-study-specific research effort. In such cases, the respective roles, responsibilities, and regulatory obligations of each party will be documented in the sub-study protocol and associated agreements, while Tempus retains overall sponsorship and governance of the Olivia platform.

The Olivia platform has its own standard Terms of Use; however, for the purposes of this research, the Informed Consent Form (ICF) serves as the governing document. In the event of any conflict between the platform's standard terms and the ICF regarding research-specific rights, data protections, or liability, the terms of the ICF will prevail.

03

Conditions studied

  • Cancer
  • Solid Tumor Cancer
  • Pediatric Acute Myeloid Leukemia
  • Hematologic Malignancies

Browse trials for

Keywords

  • Registry
  • Olivia
  • De-centralized
04

In context

Hematologic Neoplasms Reclassified

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 190 across 323 observational studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Tempus AI is the lead sponsor of 14 studies on the registry; 9 are open to participants now.

Compared within Hematologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All ages (adults and pediatrics), all indications (including solid tumors and hematologic malignancies, rare and genetic diseases, patients with suspected cancer or rare diseases, and healthy patients who have or may receive Tempus testing) and are receiving clinical care in the United States and/or U.S. Territories. Pathologically confirmed cancer diagnoses required for cohort-level analyses; biomarker-specific cohorts may be defined via the sub-study.

Eligibility criteria

ONCO-OLIVIA Registry:

Inclusion Criteria:

  • Adults or children (all ages) with a confirmed diagnosis of cancer (solid tumor or hematologic ) documented in the medical record; disease-specific cohorts may further define subtypes (e.g., stage, biomarker)
  • Receiving care in the United States and/or U.S. Territories
  • Participant (and/or legally authorized representative) is able and willing to provide electronic /permission and authorization via Olivia; with re-consent at age of eighteen if applicable
  • Willing to authorize medical record retrieval under HIPAA Right of Access and/or TEFCA IAS
  • Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and optional surveys

Exclusion Criteria:

  • Not Applicable

Substudy OLV002: Pediatric Acute Myeloid Leukemia (pAML):

Inclusion Criteria:

  • Receiving or have received care in the United States and/or U.S. Territories
  • Participant (and/or legally authorized representative) is able and willing to provide electronic informed consent/permission and authorization via the platform; with re-consent at age of eighteen if applicable
  • Legally authorized representative of participant who is deceased is able and willing to provide electronic informed consent/permission and authorization via the platform
  • Willing to authorize medical record retrieval under HIPAA Right of Access and/or TEFCA IAS
  • Access to a smartphone, tablet, or web-enabled device for remote participation (directly or via caregiver) for eConsent and cohort dependent PROs/surveys
  • Pediatric patients with a confirmed diagnosis of Acute Myeloid Leukemia (AML) including the following AML subtypes per WHO/ICC classification: AML with core-binding factor rearrangements (AML-CBF), AML with inv(16) (AML-NV16), acute promyelocytic leukemia (APL), AML with KMT2A rearrangement (AML-KMT2A), AML with mutated NPM1 (AML-NPM1), AML with bZIP CEBPA mutations (AML-bZIP), AML with MECOM rearrangement

Exclusion Criteria:

- Suspected but unconfirmed acute myeloid leukemia

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Substudy OLV002: Pediatric Acute Myeloid Leukemia (pAML)

    Prospective, decentralized, participant/caregiver-mediated data registry for real-world evidence generation in pediatric AML. This is a minimal-risk, observational registry focused on pAML- intentional data collection (i.e., surveys/PROs), and associated evidence generation. Pediatric patients with confirmed AML diagnosis (eg, consented and authorized patients with completed laboratory test results and/or confirmed cancer diagnoses) in the United States. Pediatric subject's parent/legally authorized representative will consent for their participation and inclusion into the registry.

07

What researchers measure

Primary outcomes

  1. Completeness and Yield of Multi-Modal Real-World Data Capture

    Proportion of consented participants with successfully integrated and curated multimodal datasets (combining longitudinal electronic health record \[EHR\] data and genomic testing).

    Time frame: Through study completion, up to 5 years

08

Study locations

1 of 1 sites recruiting
  • Tempus AI
    Chicago, Illinois 60654, United States
    Recruiting
09

References and documents

Individual participant data

Plan to share: No — All data will be de-identified and aggregated.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2031, 59 months later.

Of 186 observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 59 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Aug 10, 2026
StartEst.
Aug 2026
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2031
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07756034
Lead sponsor
Tempus AI
Collaborators
Blood Cancer United
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jul 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Aug 10, 2026

Study contacts

Olivia Study Team
Contact
support@oliviahealth.ai
833-514-4187

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion